The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer

Jingwu Xie, Xiaoli Zhang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.

Original languageEnglish (US)
Pages (from-to)3-10
Number of pages8
JournalJournal of Genetics and Genomics
Volume43
Issue number1
DOIs
StatePublished - Jan 20 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasms
Human Genome Project
Therapeutics
Mutation
Gene Fusion
Genetic Association Studies
Melanoma
Patient Care
Genome
Pain
Genes

Keywords

  • Gene mutation
  • Lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Genetics
  • Molecular Biology

Cite this

The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer. / Xie, Jingwu; Zhang, Xiaoli.

In: Journal of Genetics and Genomics, Vol. 43, No. 1, 20.01.2016, p. 3-10.

Research output: Contribution to journalArticle

@article{65a485d2478f454298c6225f1d40704e,
title = "The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer",
abstract = "There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.",
keywords = "Gene mutation, Lung cancer, Targeted therapy",
author = "Jingwu Xie and Xiaoli Zhang",
year = "2016",
month = "1",
day = "20",
doi = "10.1016/j.jgg.2015.09.003",
language = "English (US)",
volume = "43",
pages = "3--10",
journal = "Journal of Genetics and Genomics",
issn = "1673-8527",
publisher = "Institute of Genetics and Developmental Biology",
number = "1",

}

TY - JOUR

T1 - The Impact of Genomic Profiling for Novel Cancer Therapy - Recent Progress in Non-Small Cell Lung Cancer

AU - Xie, Jingwu

AU - Zhang, Xiaoli

PY - 2016/1/20

Y1 - 2016/1/20

N2 - There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.

AB - There is high expectation for significant improvements in cancer patient care after completion of the human genome project in 2003. Through pains-taking analyses of genomic profiles in cancer patients, a number of targetable gene alterations have been discovered, with some leading to novel therapies, such as activating mutations of EGFR, BRAF and ALK gene fusions. As a result, clinical management of cancer through targeted therapy has finally become a reality for a subset of cancers, such as lung adenocarcinomas and melanomas. In this review, we summarize how gene mutation discovery leads to new treatment strategies using non-small cell lung cancer (NSCLC) as an example. We also discuss possible future implications of cancer genome analyses.

KW - Gene mutation

KW - Lung cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84957842807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957842807&partnerID=8YFLogxK

U2 - 10.1016/j.jgg.2015.09.003

DO - 10.1016/j.jgg.2015.09.003

M3 - Article

C2 - 26842989

AN - SCOPUS:84957842807

VL - 43

SP - 3

EP - 10

JO - Journal of Genetics and Genomics

JF - Journal of Genetics and Genomics

SN - 1673-8527

IS - 1

ER -